Open access · CC-BY
via OpenAlex
Performance of soluble Klotho assays in clinical samples of kidney disease
Javier A. Neyra, Orson W. Moe, Johanne Virginia Pastor, Fabiola G. Gianella, Sachdev S. Sidhu, Mark J. Sarnak, Joachim H. Ix, David A. Drew
Clinical Kidney Journal · 2019 · ▲ 58 citations
Abstract
BACKGROUND: Soluble Klotho has multiple systemic salutary effects. In animals, both acute and chronic kidney disease models display systemic Klotho deficiency. As such, there is considerable interest in investigating soluble Klotho as a biomarker in patients with different types and severity of kidney diseases. Unfortunately, there remains uncertainty regarding the best method to measure soluble Klotho in human serum samples. METHODS: Using human serum samples obtained from several clinical cohorts with a wide range of kidney function, we measured soluble Klotho using a commercial enzyme-linked immunosorbent assay (ELISA) as well as with an immunoprecipitation-immunoblot (IP-IB) assay utilizing a synthetic antibody with high affinity and specificity for Klotho. Recovery of spiking with a known amount of exogenous Klotho was tested. A subset of samples was analyzed with and without the addition of a protease inhibitor cocktail at the time of collection or after the first freeze-thaw cycle to determine if these maneuvers influenced performance. RESULTS: = 0.18, P = 0.12). Use of a protease inhibitor cocktail neither improved nor impaired performance of the IP-IB assay; however, subsequent freeze-thaw cycle resulted in a significant reduction in Klotho recovery and dissipated the correlation between Klotho levels and eGFR. With the ELISA, the use of protease inhibitor cocktail resulted in an increase in intrasubject variability. CONCLUSIONS: The IP-IB assay is preferable to the commercial ELISA to measure soluble Klotho concentrations in never-thawed serum samples of humans with varying severity of kidney disease. However, due to the labor-intensive nature of the IP-IB assay, further research is needed to secure an assay suitable for high-throughput work.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1093/ckj/sfz085
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Neyra, J.A., Moe, O.W., Pastor, J.V., Gianella, F.G., Sidhu, S.S., Sarnak, M.J., Ix, J.H., & Drew, D.A. (2019). Performance of soluble Klotho assays in clinical samples of kidney disease. <em>Clinical Kidney Journal</em>. https://doi.org/10.1093/ckj/sfz085
Vancouver
Neyra JA, Moe OW, Pastor JV, Gianella FG, Sidhu SS, Sarnak MJ, et al. Performance of soluble Klotho assays in clinical samples of kidney disease. Clinical Kidney Journal. 2019. doi:10.1093/ckj/sfz085.
BibTeX
@article{javier2019Perfor,
title = {Performance of soluble Klotho assays in clinical samples of kidney disease},
author = {Javier A. Neyra and Orson W. Moe and Johanne Virginia Pastor and Fabiola G. Gianella and Sachdev S. Sidhu and Mark J. Sarnak and Joachim H. Ix and David A. Drew},
journal = {Clinical Kidney Journal},
year = {2019},
doi = {10.1093/ckj/sfz085},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Advances in experimental medicine and biology 2012
Citation only
Klotho and βKlotho
BMC Nephrology 2012
Open access · CC-BY
Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease
PubMed 2017
Preprint
[Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].
PLoS ONE 2013
Open access · CC-BY
A Decreased Level of Serum Soluble Klotho Is an Independent Biomarker Associated with Arterial Stiffness in Patients with Chronic Kidney Disease
International Journal of Molecular Sciences 2023
Open access · CC-BY
Association of Klotho with Coronary Artery Disease in Subjects with Type 2 Diabetes Mellitus and Preserved Kidney Function: A Case-Control Study
Chin J Postgrad Med 2014
Citation only